The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus
-
- Clément Fage
- Research Center in Infectious Diseases of the CHUQ‐CHUL and Laval University Québec City Québec Canada
-
- Andrés Pizzorno
- Research Center in Infectious Diseases of the CHUQ‐CHUL and Laval University Québec City Québec Canada
-
- Chantal Rhéaume
- Research Center in Infectious Diseases of the CHUQ‐CHUL and Laval University Québec City Québec Canada
-
- Yacine Abed
- Research Center in Infectious Diseases of the CHUQ‐CHUL and Laval University Québec City Québec Canada
-
- Guy Boivin
- Research Center in Infectious Diseases of the CHUQ‐CHUL and Laval University Québec City Québec Canada
書誌事項
- 公開日
- 2017-08-25
- 権利情報
-
- http://onlinelibrary.wiley.com/termsAndConditions#vor
- DOI
-
- 10.1002/jmv.24911
- 公開者
- Wiley
この論文をさがす
説明
<jats:sec><jats:label/><jats:p>The combination of azithromycin, an immunomodulator, with oseltamivir was compared to oseltamivir monotherapy in a lethal BALB/c model of influenza A(H1N1)pdm09 infection. Groups of 14‐16 mice received oral oseltamivir (10 mg/kg once daily for 5 days, starting at day 2 post‐inoculation) alone or combined to azithromycin (a single 100 mg/kg dose, injected intraperitoneally at day 3 post‐inoculation). Based on survival rates, lung viral titers, and pro‐inflammatory cytokine levels, the combination therapy did not provide obvious additional clinical/virological benefits over oseltamivir monotherapy. Additional studies are still needed to better define the potential role of adjunctive immunomodulatory therapy for severe influenza infections.</jats:p></jats:sec>
収録刊行物
-
- Journal of Medical Virology
-
Journal of Medical Virology 89 (12), 2239-2243, 2017-08-25
Wiley